Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430921 · ClinicalTrials.gov registry record · NA
Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment
A NA study, sponsored by Cutera.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT03430921: Completed NA study, sponsored by Cutera.
NCT03430921 is a NA study that has completed, run by Cutera. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03430921, a NA study, has completed, sponsored by Cutera.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of moderate to severe acne scars.
Primary Outcome
An improvement in Acne Scarring of at least one point on the Acne Scar Assessment Scale (ASAS):(1=clear scarring, 2=Very Mild scarring, 3=Mild scarring, 4=Moderate scarring or 5=Severe scarring) at the 12 weeks post final treatment
Interventions
- DEVICE Enlighten™ Laser and a MLA Attachment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2018-05-30 |
| Phase | NA |
What the finished NCT03430921 record still lists
NCT03430921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Enlighten™ Laser and a MLA Attachment is the first listed.
NCT03430921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03430921 about?
NCT03430921 is a clinical study titled "Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment". The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of moderate to severe acne scars.
What is the current status of trial NCT03430921?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2017-08-15. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT03430921?
The interventions under investigation include: Enlighten™ Laser and a MLA Attachment (DEVICE).
Who is sponsoring clinical trial NCT03430921?
This trial is sponsored by Cutera, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03430921's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI